Anti-Human IL-17A Recombinant Antibody (SAA0387) (HS856207)

Name: Anti-Human IL-17A Recombinant Antibody (SAA0387)
Brand: abinScience
SKU: HS856207
Price: 196 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

50ug
100ug

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HS856207
Reactividad de especies	Human
Aplicaciones	ELISA, FCM
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG4, kappa
ID de clon	SAA0387
Aplicaciones probadas	FCM
Objetivo	CTLA-8, CTLA8, Cytotoxic T-lymphocyte-associated antigen 8, IL-17, IL-17A, IL17, IL17A, Interleukin-17A
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	Q16552
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Fondo	Interleukin-17A (IL17A) is a ~17 kDa protein. Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites. IL17A is the therapeutic target of secukinumab (Cosentyx). 1. Boisson, B. et al. (2013) Immunity 39, 676-86. PMID: 24120361 2. Kuestner, RE. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 5462-73. PMID: 17911633 3. Wright, JF. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 2799-805. PMID: 18684971 4. Liu, C. et al. (2009) Science signaling 2, ra63. PMID: 19825828 5. Puel, A. et al. (2011) Science (New York, N.Y.) 332, 65-8. PMID: 21350122 6. Fossiez, F. et al. (1996) The Journal of experimental medicine 183, 2593-603. PMID: 8676080
Nota	For research use only.

Imágenes

Flow Cytometry

Flow-cytometry using anti-human IL17A antibody.IL17A Transfected CHO cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human IL17A antibody monoclonal antibody (Catalog # HS856207 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-human antibody (Catalog # HF690414) and cells analysed on a NovoCyte Flow Cytometer.
Flow Cytometry

Flow-cytometry using anti-human IL17A antibody.Human Jurkat cell line were stained with an irrelevant antibody (Blue Histogram) or an anti-human IL17A antibody monoclonal antibody (Catalog # HS856207 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-human antibody (Catalog # HF690414) and cells analysed on a NovoCyte Flow Cytometer.